In summary, our findings suggest that CDK9 inhibitors induce the apoptosis of B-ALL cells by inhibiting c-Myc-mediated glycolytic metabolism, thus providing a new strategy for the treatment of B-ALL. The gene discussed is CDK9; the disease is precursor B-cell acute lymphoblastic leukemia.